The use of Glucagon in the Termination of Insulin Coma

Abstract

Glucagon, the hyperglycaemic glycogenolytic factor of the pancreas, was discovered by Kimball and Murlin in 1923 (1). It was crystallized by Staub, Sinn and Behrens in 1953 (2, 3). Glucagon is believed to cause a rise in blood sugar by acting at the site of liver Phosphorylase—converting inactive Phosphorylase to active Phosphorylase (4).